lymphocytes

[Proceedings of the National Academy of Sciences of the United States of America] The authors developed a platform integrated with a newly curated tumor surfaceome classifier that allowed profiling of primary 3D cultures and intact patient glioma tumors with preserved tissue architecture.

[Intellia Therapeutics, Inc.] Intellia Therapeutics, Inc. announced that the first patient has been dosed with NTLA-5001, the company’s ex vivo CRISPR/Cas9 genome editing candidate for the treatment of AML.

[Science Translational Medicine] Reduced-intensity conditioning for HLA-haploidentical hematopoietic cell transplantation was augmented with same-donor memory-like natural killer (NK) cells on day +7 and 3 weeks of N-803 to treat patients with relapsed/refractory AML in a clinical trial.

[Blood] As BCL2 was an important determinant of survival of both myeloid progenitor and B cells, researchers investigated whether clinical and molecular abnormalities arise in the myeloid compartment during long-term continuous venetoclax treatment of chronic lymphocytic leukemia in 89 patients.

[Bone Marrow Transplantation] Scientists investigated whether gilteritinib, a selective FLT3 inhibitor, could enhance graft-versus-leukemia effects against FLT3 internal tandem duplication mutant transfected Ba/F3 leukemia in mice.

[Molecular Therapy] Investigators treated three children suffering from severe, therapy-refractory GvHD with polyclonally expanded regulatory T cells generated from the original stem cell donor.